/ CompletedNot Applicable A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.
100 Clinical Results associated with Stormont-Vail HealthCare, Inc.
0 Patents (Medical) associated with Stormont-Vail HealthCare, Inc.
100 Deals associated with Stormont-Vail HealthCare, Inc.
100 Translational Medicine associated with Stormont-Vail HealthCare, Inc.